Pathology: mHNSCC - L2 - all population; mHNSCC - L2 - PDL1 negative; mHNSCC - L2 - PDL1 positive;
| mHNSCC - L2 - all population | mHNSCC - L2 - PDL1 negative | mHNSCC - L2 - PDL1 positive | ||||||
| EAGLE (D vs ICC), 2019 | EAGLE (DT vs ICC), 2019 | CheckMate 141, 2016 | KEYNOTE-040 (all population), 2018 | CONDOR (DT vs D ; PDL1 TC<25%), 2019 | CONDOR (DT vs T ; PDL1 TC<25%), 2019 | KEYNOTE-040 (CPS >1), 2018 | ||
| durvalumab plus tremelimumab | 3 | T1 | T1 | T1 | ||||
| pembrolizumab alone | 2 | T1 | T1 | |||||
| durvalumab alone | 1 | T1 | T0 | |||||
| nivolumab alone | 1 | T1 | ||||||
| tremelimumab | 0 | T0 | ||||||
| Standard of Care (SoC) | 0 | T0 | T0 | T0 | T0 | T0 | ||